March 4th 2025
Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a manageable safety profile.
March 4th 2025
March 3rd 2025
February 28th 2025
January 5th 2025
January 1st 2025
December 31st 2024
December 29th 2024
March 3rd 2025
February 23rd 2025
February 22nd 2025
February 1st 2025